

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for 6 Months of Age and Older



The table below provides guidance for COVID-19 vaccination schedules based on age and medical condition. Scheduling considerations include:

- Administer the appropriate vaccine product based on the recipient's age and the product's age indications.
- COVID-19 vaccines may be administered on the same day as other vaccines.
- Doses administered at any time after the intervals outlined below are valid.

Detailed information can be found in CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, see: www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age

Type	Product*	Recipient Age	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses ^{†‡}	Doses	Interval Between Doses ^{†‡}
mRNA vaccine	Moderna (Blue vial cap with magenta-bordered label)	6 months through 5 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks [†]	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	Moderna (Blue vial cap with purple-bordered label)	6 through 11 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks [†]	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	Moderna (Red vial cap with blue-bordered label)	12 through 17 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks [†]	Dose 1 to 2	At least 4 weeks
					Dose 2 to 3	At least 4 weeks
	Pfizer-BioNTech (Maroon vial cap with maroon-bordered label)	6 months through 4 years	Total number: 3 doses		Total number: 3 doses	
			Dose 1 to 2	At least 3–8 weeks [†]	Dose 1 to 2	At least 3 weeks
			Doses 2 and 3	At least 8 weeks	Dose 2 to 3	At least 8 weeks
Pfizer-BioNTech (Orange vial cap with orange-bordered label)	5 through 11 years	Total number: 3 doses		Total number: 4 doses		
		Dose 1 to 2	At least 3–8 weeks [†]	Dose 1 to 2	At least 3 weeks	
		Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks	
Pfizer-BioNTech (Purple vial cap with a purple-bordered label or gray vial cap with gray-bordered label)	12 years through 17 years	Total number: 3 doses		Total number: 5 doses		
		Dose 1 to 2	At least 3–8 weeks [†]	Dose 1 to 2	At least 3 weeks	
		Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks	
				Dose 3 to 4	At least 3 months	
		Dose 4 to 5	At least 4 months			

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose. Any COVID-19 vaccine product (age appropriate) may be administered for a booster dose. It does not need to be the same product used for the primary series.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for 6 Months of Age and Older



Table 2. Immunization Schedule for Persons 18 Years of Age

Type	Product*	Recipient Age	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses ^{††}	Doses	Interval Between Doses ^{††}
mRNA vaccine	Moderna (Red vial cap with a blue-bordered label)	18 years and older	Total number: 3 or 4 doses		Total number: 5 doses	
			Dose 1 to 2	At least 4–8 weeks [‡]	Dose 1 to 2	At least 4 weeks
			Dose 2 to 3 [§]	At least 5 months	Dose 2 to 3	At least 4 weeks
			Dose 3 to 4 [§]	At least 4 months for persons ages 50 years and older	Dose 3 to 4 [§]	At least 3 months
	Dose 4 to 5 [§]	At least 4 months				
	Pfizer-BioNTech (Purple vial cap with a purple-bordered label or gray vial cap with gray-bordered label)	18 years and older	Total number: 3 or 4 doses		Total number: 5 doses	
			Dose 1 to 2	At least 3-8 weeks [‡]	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 5 months [§]	Dose 2 to 3	At least 4 weeks
Dose 3 to 4			At least 4 months for persons ages 50 years and older [§]	Dose 3 to 4 [§]	At least 3 months	
	Dose 4 to 5 [§]	At least 4 months				
Protein subunit vaccine	Novavax	18 years and older	Total number: 2 doses [‡]		Total number: 2 doses	
			Dose 1 to 2	At least 3–8 weeks [‡]	Dose 1 to 2	At least 3 weeks
Adenovirus vector vaccine	Janssen*	18 years and older	Total number: 2 or 3 doses		Total number: 4 doses	
			Dose 1 to 2	At least 8 weeks	Dose 1 to 2	At least 4 weeks (mRNA vaccine) [¶]
			Dose 2 to 3	At least 4 months for persons ages 50 years and older (mRNA vaccine)**	Dose 2 to 3	At least 8 weeks*
Dose 3 to 4	At least 4 months (mRNA vaccine) [¶]					

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate COVID-19 vaccine product may be administered at least 28 days after the first dose. An mRNA (Moderna, Pfizer-BioNTech) and Novavax COVID-19 vaccines are recommended for the primary series. The mRNA vaccines are recommended for booster doses. Novavax COVID-19 Vaccine is not authorized for booster doses. Janssen COVID-19 Vaccine should only be used in limited situations.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA or Novavax COVID-19 Vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

§ mRNA vaccine recommended. Novavax COVID-19 Vaccine is not authorized for booster dose.

¶ mRNA vaccine must be used.

** People ages 18–49 years: Those who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the Janssen booster dose.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for 6 Months of Age and Older




Special Situations When Vaccinating Children

1. COVID-19 vaccine from the same manufacturer should be used for the primary series. If a different manufacturer is administered, follow the guidance below:

- If a dose of the age-appropriate product from BOTH Moderna and Pfizer-BioNTech COVID-19 is given, count both doses if the recommended interval between doses has been met.
 - Complete the series following the Pfizer-BioNTech 3-dose schedule using an age-appropriate vaccine from either manufacturer. See examples.
 - Repeating doses is not recommended.
- This guidance applies to:
 - All eligible children, including those who are moderately or severely immunocompromised.
 - Vaccines from both manufacturers, regardless which vaccine was given first.

Examples:

Vaccination history: 1 dose of Pfizer-BioNTech and 1 dose of Moderna COVID-19 vaccines.



2. Children who have a birthday before completing the primary series

- Vaccine product and dosage (amount of vaccine given) is determined by the recipient's age.
- CDC recommends administering the age-appropriate product based on the child's age the day the vaccine will be administered – even if the series was started with a vaccine with younger age indications.
- If a dose(s) of the vaccine product indicated for the younger age group is administered, count the dose(s). Revaccination is not indicated. It is NOT considered a vaccine administration error.
- For detailed guidance see:
 - Pfizer-BioNTech COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group (www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf)
 - Moderna COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group (www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf)

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for 6 Months of Age and Older



Table 3. COVID-19 Vaccine Products Summary

Product*	Age Indications†	Diluent	Dose/Injection Amount	
Type: mRNA vaccine				
Moderna (Blue vial cap with magenta-bordered label)	6 months through 5 years	NONE	Any dose in the primary series. Booster doses are not recommended for this age group.	25 µg/ 0.25 mL
Moderna (Blue vial cap with purple-bordered label)	6 through 11 years	NONE	Any dose in the primary series. Booster doses are not authorized for children, ages 6 through 11 years, who received a Moderna primary series.	50 µg/0.5 mL
	18 years and older	NONE	Booster dose only.	50 µg/0.5 mL
Moderna (Red vial cap with blue-bordered label)	12 years and older	NONE	Any dose in the primary series. Booster doses are not authorized for adolescents, ages 12 through 17 years, who received a Moderna primary series.	100 µg/ 0.5 mL
	18 years and older	NONE	Any dose in the primary series.	100 µg/ 0.5 mL
			Booster dose	50 µg/ 0.25 mL
Pfizer-BioNTech (Maroon vial cap with maroon-bordered label)	6 months through 4 years	2.2 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series. Booster doses are not recommended for this age group.	3 µg/0.2 mL
Pfizer-BioNTech (Orange vial cap with orange-bordered label)	5 through 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series and booster doses.	10 µg/0.2 mL
Pfizer-BioNTech (Purple vial cap with a purple-bordered label)	12 years and older	1.8 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series and booster doses.	30 µg/0.3 mL
Pfizer-BioNTech (Gray vial cap with a gray-bordered label)	12 years and older	NONE	Any dose in the primary series and booster doses.	30 µg/0.3 mL
Product	Age Indications	Diluent	Dose/Injection Amount	
Type: Protein sub unit vaccine				
Novavax (Royal blue cap)	18 years and older	NONE	Any dose in the primary series. Persons who received a Novavax COVID-19 Vaccine primary series are not eligible for booster doses (any product).	5 µg rS and 50 µg of Matrix-M™ adjuvant/0.5 mL
Product	Age Indications	Diluent	Dose/Injection Amount	
Type: Viral vector vaccine				
Janssen‡ (Blue Cap)	18 years and older	NONE	Primary and 1st booster dose.	5×10 ¹⁰ viral particles/0.5 mL

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate COVID-19 vaccine product may be administered at least 28 days after the first dose. An mRNA (Moderna, Pfizer-BioNTech) and Novavax COVID-19 vaccines are recommended for the primary series. The mRNA vaccines are recommended for booster doses. Novavax COVID-19 Vaccine is not authorized for booster doses. Janssen COVID-19 Vaccine should only be used in limited situations.

† Administer the appropriate vaccine product based on the recipient's age and the vaccine product's age indications.

‡ Age-appropriate mRNA (Moderna or Pfizer-BioNTech) and Novavax vaccines are recommended for primary vaccination. Janssen COVID-19 Vaccine should only be used in limited situations for primary or 1st booster dose. It cannot be used for 2nd booster doses.

CDC Resources

CDC COVID-19 vaccine clinical training and materials at: www.cdc.gov/vaccines/covid-19/info-by-product/index.html

CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at: www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series

CDC Vaccine administration clinical materials at: www.cdc.gov/vaccines/hcp/admin/resource-library.html

CDC Vaccine Storage and Handling Toolkit at: www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html